Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference29 articles.
1. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL (2015) Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 21:2445–2452
2. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331–1337
3. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/statfacts/html/lungb.html. Accessed 18 Apr 2019
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2018) Non-small cell lung cancer. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed 18 Apr 2019
5. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, Lewis MD, Doroshow J (2005) A phase I pharmacokinetic and target validation study of novel anti-tubulin agent E7389: a California Cancer Consoritum [abstract]. J Clin Oncol 23(16 suppl):3036
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献